New anticoagulant drugs

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 95S-107S

  Weitz, J I ^a   Hirsh, J ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [(2' AMINOSULFONYL 1,1' BIPHENYL 4 YL)CARBAMOYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; ARGININE DERIVATIVE; BLOOD CLOTTING INHIBITOR; BOTHROJARACIN; COUMARIN ANTICOAGULANT; CVS 1123; DERMATAN SULFATE; DEXTRO PHENYLALANYLPROLYL 5 AMINOVALERYL 5 AMINOVALERYLASPARTYLPHENYLALANYLGLUTAMYLPROLYLISOLEUCYLPROLYLLEUCINE; DIPETALIN; EFEGATRAN; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; L 372236; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; N (9 HYDROXY 9 FLUORENECARBOXY)PROLINE (4 AMINOCYCLOHEXYLMETHYL)AMIDE; NAPSAGATRAN; PENTASACCHARIDE; PEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR; PROCARBOXYPEPTIDASE B; RHODIIN; S 18326; THROMBIN INHIBITOR; TICK ANTICOAGULANT PEPTIDE; TISSUE FACTOR PATHWAY INHIBITOR; TRIABIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIMELAGATRAN; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYSIS; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; THROMBOGENESIS; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0035128439     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.95S     Document Type: Conference Paper

References (149)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Molecular cellular biology of blood coagulation
3. Tissue factor expression during monocyte-macrophage differentiation
4. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity
5. Tissue factor-dependent autoactivation of human blood coagulation factor
6. Factor XI activation by thrombin and factor XIa
7. Heparin
8. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta
9. Tissue factor pathway inhibitor
10. The protein C pathway: New insights
11. The plasminogen (fibrinolytic) system
12. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
13. Oral anticoagulant drugs
14. Low molecular weight heparins
15. Insight into the mechanism of action of heparin cofactor II
16. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate: Pharmacologic considerations
17. Oral delivery of anticoagulant doses of heparin: A randomized, double-blind controlled study in humans
18. Orally administered heparin for preventing deep venous thrombosis
19. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer: DOS (dermatan sulphate in oncologic surgery) Study Group
20. Bioavailability of desmin, a low molecular weight dermatan sulphate, after subcutaneous administration to healthy volunteers
21. Structural features of dermatan sulfates and their relationship to anticoagulant antithrombotic activities
22. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
23. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors
24. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
25. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
26. Cloning and expression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalis
27. The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin
28. Kinetics of inhibition of thrombin by hirudin
29. The structure of a complex of recombinant hirudin and human α-thrombin
30. Hirudins: Antithrombin anticoagulants
31. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia
32. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis
33. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
34. Recombinant hirudin as an anticoagulant in open-heart surgery; a case report
35. New treatment options for heparin-induced thrombocytopenia
36. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
37. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
38. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
39. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial
40. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors or thrombin
41. Thrombin-specific inhibition by and slow cleavage of hirulog-1
42. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina: Hirulog Angioplasty Study Investigators
43. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina: Hirulog Angioplasty Study Investigators
44. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans
45. Bothrojaracin: A potent two-site-directed thrombin inhibitor
46. Inhibition of thrombin-induced cellular effects by a highly potent thrombin inhibitor isolated from the assassin bug Dipetalogaster maximus
47. Triabin, a highly potent exosite inhibitor of thrombin
48. Two heads are better than one: Crystal structure of the insect-derived double domain Kazal inhibitor rhodniin in complex with thrombin
49. Design and synthesis of potent and highly selective thrombin inhibitors
50. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass
51. Single and repeated oral dosing of H376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects
52. Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use
53. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminogcyclohexyl-methyl amide (L-372,460): Coapplication of structure-based design and rapid multiple analogue synthesis on solid support
54. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury
55. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat
56. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
57. Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis: ADVENT Investigators
58. Intravenous treatment of acute deep vein thrombosis (DVT) with melagatran, a synthetic low molecular weight thrombin inhibitor
59. In vitro and in vivo neutralization of the anticoagulant effect of the thrombin inhibitor napsagatran by S205A-thrombin
60. 2Cl: A selective affinity label for thrombin
61. The selective inhibition of thrombin by peptides of boroarginine
62. Acute toxicity of synthetic thrombin inhibitors caused by inhibition of complement factor I
63. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H
64. Highly selective tripeptide thrombin inhibitors
65. Challenges in the development of orally bioavailable thrombin active site inhibitors
66. In vivo anticoagulant and antiplatelet effect of D-Phe-Arg-Pro-H and D-MePhe-Pro-Arg-H
67. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor
68. Antithrombotic properties of S18326: A new potent orally active tripeptide boronic acid thrombin inhibitor
69. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog
70. Evaluation of a novel orally active direct inhibitor of thrombin in animal models of thrombosis
71. Selection of single-stranded DNA molecules that bind and inhibit human thrombin
72. The structure of α-thrombin inhibited by a 15-mer single stranded DNA aptamer
73. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes
74. Evidence for allosteric linkage between exosites 1 and 2 of thrombin
75. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithromboric agent in rodent models of arterial and venous thrombosis - Comparisons with heparin, r-Hirudin, hirulog, inogatran and argatroban
76. Effective use BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (+ PA) in a rat arterial thrombolysis model
77. BCH-2763, a new potent thrombin inhibitor, is an effective inhibitor of venous thrombosis in rats
78. Diarylsulfonamides as selective, non-peptide thrombin inhibitors
79. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation
80. Hemophilia
81. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model
82. A monoclonal antibody to factor IX that inhibits the factor VIII: Ca potentiation of factor X activation
83. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis
84. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats
85. Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa
86. Isolation and characterization of antistasin
87. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech
88. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies
89. Biochemical and pharmacologic characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa
90. Nonpeptide factor Xa inbibitors: I. Studies with SF303 and SK549, a new antithrombotic
91. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors
92. Antistasin: A leech-derived inhibitor of factor Xa: Kinetic analysis of enzyme inhibition and identification of the reactive site
93. Biochemical and pharmacologic properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide
94. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon
95. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent
96. A peptide derived from a tissue factor loop region functions as a tissue factor-factor VIIa antagonist
97. Synthetic peptide analogs of tissue factor and factor VII that inhibit factor Xa formation by the tissue factor/factor VII complex
98. Antithrombotic and anti-lesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
99. Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
100. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor
101. Anticoagulant repertoire of the hookworm Ancylostoma caninum
102. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor
103. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa
104. Antithrombin-mediated inhibitor of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin
105. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces: Comparisons with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity
106. Kunitz domain inhibitors of tissue factor-factor VIIa: I. Potent inhibitors selected from libraries by phage display
107. Molecular events that control the protein C anticoagulant pathway
108. An update on clinical and basic aspects of the protein C anticoagulant pathway
109. Direct expression of recombinant activated human protein C, a serine protease
110. Glycosylation of human protein C affects its secretion, processing, functional activities and activation by thrombin
111. Recombinant human protein C derivatives: Altered response to calcium resulting in enhanced activation by thrombin
112. Mutation of Glu 80 to Lys results in a protein C mutant, that no longer requires Ca2+ for rapid activation by the thrombin-thrombomodulin complex
113. Antithrombotic efficacy in the guinea pig of a derivative of human protein C with enhanced activation by thrombin
114. Thrombomodulin structure and function
115. Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells
116. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
117. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III
118. Recombinant human thrombomodulin: Regulation of cofactor activity and anticoagulant function by a glycosaminoglycan side chain
119. Urinary thrombomodulin, its isolation and characterization
120. Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: Potential regulation of functionality by glycosyltransferase competition for serine 474
121. Conversion of thrombin into an anticoagulant by protein engineering
122. Modulation of thrombin's procoagulant and anticoagulant properties
123. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator
124. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil
125. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: A potential link between lipid lowering and fibrinolysis
126. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into β-sheet A
127. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
128. Low molecular weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
129. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
130. Inducible carboxypeptidase activity: A role in clot lysis in vivo
131. A novel approach to arterial thrombolysis
132. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains
133. The roles of fibrinogen and fibrin in hemostasis and thrombosis
134. Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function
135. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro
136. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii
137. Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity
138. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots
139. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin and placebo
140. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
141. Prolonged thromboprophylaxis after hip replacement surgery: Results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
142. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
143. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
144. The long-term clinical course of acute deep venous thrombosis
145. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
146. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
147. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
148. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO IIb trial
149. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)